In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 676 ( 2022-12-21)
Abstract:
Defending against GVHDAcute graft-versus-host disease (aGVHD) occurring after allogeneic hematopoietic stem cell transplantation is a major cause of mortality for patients. Treatment options for aGVHD are limited, and additional therapeutics are urgently needed. Here, Rückert 〈 italic 〉 et al. 〈 /italic 〉 identified human β-defensin-2 (hBD-2), a host-defense peptide, as a candidate treatment for aGVHD. The authors found that, in mice that received stem cell transplantation, oral hBD-2 treatment modulated the intestinal microbiome, reduced neutrophil infiltration into the ileum, and controlled alloreactive T cell responses, all while leaving the graft-versus-leukemia effect intact. These findings highlight the potential for hBD-2 as a therapeutic option for aGVHD.—CM
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abp9675
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Bookmarklink